Products Ofatumumab
Ofatumumab Approved Completed 🔥 Hot Relapse Remitting Multiple Sclerosis
Relapse Remitting Multiple Sclerosis
Jan 25, 2022 → Feb 11, 2026
About Ofatumumab Ofatumumab is a approved stage product being developed by Novartis for Relapse Remitting Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT05084638. Target conditions include Relapse Remitting Multiple Sclerosis.
Clinical Trials (10) NCT ID Phase Status Start Completion Indication NCT06345157 Pre-clinical Active Jul 30, 2024 Jun 30, 2026 Multiple Sclerosis, Relapsing-Remitting NCT06167642 Pre-clinical Recruiting May 22, 2023 Mar 1, 2027 Multiple Sclerosis NCT05199571 Approved Completed Jul 22, 2022 Feb 13, 2025 Relapsing Multiple Sclerosis NCT05171972 Pre-clinical Active Jan 29, 2022 Jun 30, 2025 Relapsing Remitting Multiple Sclerosis NCT05084638 Approved Completed Jan 25, 2022 Feb 11, 2026 Relapse Remitting Multiple Sclerosis NCT04869358 Approved Completed May 27, 2021 Jun 13, 2023 Relapsing Multiple Sclerosis NCT04486716 Phase 3 Completed Oct 19, 2020 Oct 21, 2024 Relapsing Multiple Sclerosis NCT04353492 Phase 3 Completed Jul 14, 2020 Mar 11, 2025 Relapsing Multiple Sclerosis NCT01848145 Phase 2 Completed Jul 1, 2013 Mar 1, 2017 Chronic Lymphocytic Leukemia NCT01039376 Phase 3 Terminated May 6, 2010 Jun 26, 2018 Leukaemia, Lymphocytic, Chronic
Competing Products 20 competing products in Relapse Remitting Multiple Sclerosis
See all competitors Product Company Stage Hype Score Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 VIP152 + BTKi Vincerx Pharma Phase 1 eFT508 + Avelumab eFFECTOR Therapeutics Phase 2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 AC220 Daiichi Sankyo Phase 1 Valemetostat Tosylate Daiichi Sankyo Phase 2 Linsitinib Astellas Pharma Phase 2 AGS67E Astellas Pharma Phase 1 Mitoxantrone Hydrochloride Liposome & Enlonstobart Sun Pharmaceutical Phase 1/2 Lenvatinib Eisai Phase 2 Farletuzumab + Placebo Eisai Phase 2 Tazemetostat Eisai Phase 2 Tazemetostat Eisai Phase 1 Eribulin mesylate Eisai Phase 2 ME-401 Kyowa Kirin Phase 1 KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6 Kyowa Kirin Phase 1 Mogamulizumab Kyowa Kirin Phase 2 ONO-4685 Ono Pharmaceutical Phase 1 ONO-4685 Ono Pharmaceutical Phase 1
Other Products from Novartis